This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr.

This March, LUNGevity Foundation partnered with CURE for their ”Speaking Out” video series, featuring Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation. This interview with Dr. Moore delves into recent breakthroughs in the treatment of small cell lung cancer (SCLC). Dr.

Join small cell lung cancer expert Lauren Byers, MD, as she covers the key things patients need to know about SCLC in 30 minutes.  

Dr. Byers is a professor in the Department of Thoracic-Head & Neck Medical Oncology at MD Anderson Cancer Center. She is also a physician-scientist and a member of LUNGevity’s Scientific Advisory Board. 

The following topics are discussed at the times indicated:

0:00 – 5:03 Introduction and explanation of what small cell lung cancer (SCLC) is

5:03 – 8:49 Key features and common symptoms 

In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient.  

These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements.  

Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic questions to ask and get answered before making a decision are:

The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments.

Phases of a Clinical Trial:

1. Safety of the new treatment 
2. Does the cancer respond to the treatment 
3. Is this new treatment better than the current options 
4. Studies the long-term benefits and side effects

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts. 

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23.  

The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are available until December 21.

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S.

Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled to welcome our panelists: Balazs Halmos, MD, a thoracic medical oncologist from Montefiore Medical Center in New York; Elizabeth Ravera, a patient navigator at Montefiore; and a patient living with lung cancer who tested positive for the ALK biomarker. The panel is moderated by LUNGevity's Amy Moore, PhD, VP of Global Engagement and Patient Partnerships.